Co­herus looks to dis­rupt Am­gen’s $4B Neu­las­ta fran­chise as an­a­lysts look for a deep dis­count on its copy­cat price

De­spite be­ing the run­ner-up in the race to a US ap­proval for a biosim­i­lar of Neu­las­ta, an­a­lysts are watch­ing to see if lit­tle Co­herus could gain quick trac­tion if they sell theirs at a big dis­count to My­lan’s ri­val.

On Fri­day, Co­herus said it had se­cured the FDA’s nod for a copy­cat ver­sion of Am­gen’s block­buster prod­uct — com­ing sec­ond to My­lan $MYL and In­di­an part­ner Bio­con in the race to mar­ket a biosim­i­lar for Neu­las­ta in the more lu­cra­tive US mar­ket. Co­herus’ biosim­i­lar, Uden­cya, was grant­ed Eu­ro­pean ap­proval in Sep­tem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.